Vietnam is strengthening its life sciences and clinical diagnostics capabilities, creating growing demand for flow cytometry technologies across hospitals, research institutes and the biotechnology sector.
Although no standalone valuation has been published for Vietnam's flow cytometry market, industry analysis estimates the sector is currently worth US$42–55 million in 2025 and is projected to reach US$65–85 million by 2030.
Flow cytometry has become one of the most important analytical technologies in modern biomedical research and clinical diagnostics. By rapidly analysing thousands of individual cells per second, it enables clinicians and researchers to identify cell populations, diagnose disease, monitor immune function and support drug discovery with exceptional speed and accuracy.
The market includes:
- Flow cytometers
- Fluorescence-activated cell sorters (FACS)
- Imaging flow cytometry platforms
- Reagents and consumables
- Monoclonal antibodies
- Cell analysis software
- Sample preparation systems
- Quality control materials
- Service and maintenance
- Data analysis and AI-enabled software
Several long-term trends are driving market growth across Vietnam:
- Rising cancer incidence requiring advanced immunophenotyping.
- Expansion of precision medicine programmes.
- Growth in stem cell and regenerative medicine research.
- Increasing pharmaceutical and biotechnology R&D investment.
- Expansion of clinical diagnostics laboratories.
- Growing use of flow cytometry in infectious disease and immunology research.
- Continued investment in university and government research infrastructure.
Vietnam's broader life sciences sector is expanding rapidly. According to IMARC Group, the country's Life Science Tools Market reached US$712.2 million in 2025 and is forecast to grow to US$1.41 billion by 2034. Flow cytometry is identified as one of the principal technology platforms alongside PCR, sequencing, separation technologies and mass spectrometry, reflecting its increasing importance across research and clinical laboratories.
Clinical diagnostics is also creating additional demand for flow cytometry. IMARC Group estimates Vietnam's In Vitro Diagnostics (IVD) Market reached US$349.3 million in 2025 and is projected to grow to US$503.6 million by 2034. As hospitals adopt more sophisticated diagnostic testing for haematological malignancies, immune disorders and infectious diseases, flow cytometry is becoming an increasingly valuable clinical tool.
Globally, the technology continues to evolve rapidly. IMARC Group estimates the Global Flow Cytometry Market reached US$6.6 billion in 2025 and is expected to reach US$11.7 billion by 2034. Growth is being driven by expanding applications in immuno-oncology, personalised medicine, cell and gene therapy, stem cell research and pharmaceutical drug development. Reagents and consumables remain the largest product segment, while pharmaceutical and biotechnology companies are among the fastest-growing end users.
Artificial intelligence is beginning to transform flow cytometry by automating complex data analysis, improving cell classification and reducing interpretation time. Recent research demonstrates that deep learning algorithms can significantly improve automated cell population identification, while emerging imaging flow cytometry platforms combine high-speed cellular analysis with advanced image processing to generate richer biological insights.
Vietnam is also benefiting from increased investment in translational research, vaccine development and biopharmaceutical manufacturing, all of which rely heavily on flow cytometry for quality control, biomarker discovery and immune monitoring. As biotechnology research expands across Southeast Asia, demand for advanced cytometry platforms is expected to continue rising.
Leading manufacturers including BD Biosciences, Beckman Coulter, Sysmex, Bio-Rad Laboratories, Thermo Fisher Scientific, Agilent Technologies, Miltenyi Biotec, Sony Biotechnology, Cytek Biosciences and Luminex (DiaSorin) continue to introduce increasingly automated, high-parameter and AI-enabled cytometry systems capable of supporting both clinical diagnostics and advanced biomedical research.
As Vietnam continues to invest in precision medicine, cancer care and life sciences research, flow cytometry will become an increasingly important enabling technology across healthcare and biotechnology. For manufacturers of cytometers, reagents, laboratory automation systems, software platforms and research consumables, Vietnam represents one of Southeast Asia's most promising emerging markets.